ImmunityBio Earnings Call Transcripts
Fiscal Year 2026
-
The meeting re-elected all nine incumbent directors and ratified Deloitte & Touche LLP as auditor for 2026. No shareholder questions or additional nominations were received, and voting results will be reported to the SEC.
-
The conference highlighted robust clinical and commercial progress for ANKTIVA, with strong efficacy and durability in bladder and lung cancer, expanding global approvals, and a growing pipeline. Financials remain solid, and new BCG strains aim to resolve shortages. Patient outcomes and physician feedback underscore transformative impact.
-
A robust immunotherapy pipeline is driving global expansion, with ANKTIVA approved in 33 countries and strong clinical data supporting long-term cancer remission. Regulatory filings and commercial launches in the U.S., Europe, and Saudi Arabia are expected to fuel multi-billion dollar market opportunities and significant revenue growth by 2027.
Fiscal Year 2025
-
Net product revenue surged 700% to $113 million in 2025, driven by strong U.S. adoption and rapid global expansion of Anktiva, now approved in 33 countries. Net loss narrowed by $62 million, and major clinical milestones were achieved, including first-in-world lung cancer approval in Saudi Arabia.
-
The session highlighted ANKTIVA's strong uptake post-J-code, global expansion efforts, and innovative partnerships to address BCG shortages. Key milestones include regulatory progress in the U.S. and Europe, ongoing pivotal trials in lung cancer, and promising early results in glioblastoma.
-
The Cancer BioShield platform is transforming cancer care by activating NK and T cells, achieving durable remissions in bladder cancer and showing tumor-agnostic efficacy across multiple indications. Commercial momentum is strong, with global expansion, new trials in prevention and cell therapy, and a focus on regulatory advocacy and patient quality of life.